Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation

Bondarenko I., Sezer A., Kilickap S., GÜMÜŞ M., ÖZGÜROĞLU M., Gogishvili M., ...More

ANNALS OF ONCOLOGY, vol.33, 2022 (SCI-Expanded)

• Publication Type: Article / Abstract
• Volume: 33
• Publication Date: 2022
• Doi Number: 10.1016/j.annonc.2022.02.139
• Journal Name: ANNALS OF ONCOLOGY
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, CAB Abstracts, EMBASE, MEDLINE
• Open Archive Collection: AVESIS Open Access Collection
• Istanbul University Affiliated: No